Systemic AA amyloidosis is a serious and potentially fatal complication of Crohn’s disease.¹ This serious complication is associated with approximately 0.9–2.5% of patients with Crohn’s disease but renal failure due to renal amyloidosis is one of the most common causes of death for patients with Crohn’s disease.² Although drugs such as azathioprine, colchicines, and dimethylsulphoxide are suggested to delay the progression of renal amyloidosis, the efficacy of these drugs on renal amyloidosis has not been fully elucidated.² Infliximab is a chimeric anti-tumour necrosis factor α (TNF-α) monoclonal antibody. This drug has been proven …